349 related articles for article (PubMed ID: 21382149)
1. Maximizing outcomes in genitourinary cancers across the treatment continuum.
Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Bracarda S; Logothetis C; Sternberg CN; Oudard S
BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
[TBL] [Abstract][Full Text] [Related]
3. [Prostate cancer treatments in Belgium].
Kaitouni MI; Roumeguère T
Rev Med Brux; 2009 Sep; 30(4):270-8. PubMed ID: 19899373
[TBL] [Abstract][Full Text] [Related]
4. Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
Bahl A; Bellmunt J; Oudard S
BJU Int; 2012 Mar; 109 Suppl 2():14-9. PubMed ID: 22257100
[TBL] [Abstract][Full Text] [Related]
5. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
6. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
7. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
8. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
12. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
13. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
14. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
15. New treatments for localized prostate cancer.
Marberger M; Carroll PR; Zelefsky MJ; Coleman JA; Hricak H; Scardino PT; Abenhaim LL
Urology; 2008 Dec; 72(6 Suppl):S36-43. PubMed ID: 19095127
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer: opportunities for prevention.
Thompson IM; Coltman CA
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):4-10; discussion 10-1. PubMed ID: 8725886
[TBL] [Abstract][Full Text] [Related]
17. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
18. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
19. Focal therapy for prostate cancer.
Polascik TJ; Mouraviev V
Curr Opin Urol; 2008 May; 18(3):269-74. PubMed ID: 18382236
[TBL] [Abstract][Full Text] [Related]
20. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
Izawa JI; Chin JL; Winquist E
Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]